Literature DB >> 18544929

Down syndrome and the genes of human chromosome 21: current knowledge and future potentials. Report on the Expert workshop on the biology of chromosome 21 genes: towards gene-phenotype correlations in Down syndrome. Washington D.C., September 28-October 1, 2007.

M Pritchard1, R H Reeves, M Dierssen, D Patterson, K J Gardiner.   

Abstract

Down syndrome (DS), trisomy of human chromosome 21, is the most common genetic cause of intellectual disability. With an incidence in some countries as high as one in approximately 700 live births, and a complex, extensive and variably severe phenotype, Down syndrome is a significant medical and social challenge. In recent years, there has been a rapid increase in information on the functions of the genes of human chromosome 21, as well as in techniques and resources for their analysis. A recent workshop brought together experts on the molecular biology of Down syndrome and chromosome 21 with interested researchers in other fields to discuss advances and potentials for generating gene-phenotype correlations. An additional goal of the workshop was to work towards identification of targets for therapeutics that will correct features of DS. A knowledge-based approach to therapeutics also requires the correlation of chromosome 21 gene function with phenotypic features. (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18544929     DOI: 10.1159/000124384

Source DB:  PubMed          Journal:  Cytogenet Genome Res        ISSN: 1424-8581            Impact factor:   1.636


  13 in total

1.  Brain disorders: getting 'Down' to the gene.

Authors:  Lino Tessarollo
Journal:  Nat Neurosci       Date:  2010-08       Impact factor: 24.884

2.  Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions.

Authors:  Xiaolu Sturgeon; Katheleen J Gardiner
Journal:  Mamm Genome       Date:  2011-03-13       Impact factor: 2.957

Review 3.  Down syndrome: the brain in trisomic mode.

Authors:  Mara Dierssen
Journal:  Nat Rev Neurosci       Date:  2012-12       Impact factor: 34.870

Review 4.  MicroRNAs: Meta-controllers of gene expression in synaptic activity emerge as genetic and diagnostic markers of human disease.

Authors:  Stephanie Ceman; Julie Saugstad
Journal:  Pharmacol Ther       Date:  2011-01-20       Impact factor: 12.310

5.  Effects of individual segmental trisomies of human chromosome 21 syntenic regions on hippocampal long-term potentiation and cognitive behaviors in mice.

Authors:  Tao Yu; Chunhong Liu; Pavel Belichenko; Steven J Clapcote; Shaomin Li; Annie Pao; Alexander Kleschevnikov; Allison R Bechard; Suhail Asrar; Rongqing Chen; Ni Fan; Zhenyu Zhou; Zhengping Jia; Chu Chen; John C Roder; Bin Liu; Antonio Baldini; William C Mobley; Y Eugene Yu
Journal:  Brain Res       Date:  2010-10-26       Impact factor: 3.252

Review 6.  Molecular basis of pharmacotherapies for cognition in Down syndrome.

Authors:  Katheleen J Gardiner
Journal:  Trends Pharmacol Sci       Date:  2009-12-04       Impact factor: 14.819

Review 7.  Function and regulation of Dyrk1A: towards understanding Down syndrome.

Authors:  Joongkyu Park; Woo-Joo Song; Kwang Chul Chung
Journal:  Cell Mol Life Sci       Date:  2009-08-14       Impact factor: 9.261

Review 8.  Chronic high levels of the RCAN1-1 protein may promote neurodegeneration and Alzheimer disease.

Authors:  Gennady Ermak; Kelvin J A Davies
Journal:  Free Radic Biol Med       Date:  2013-01-29       Impact factor: 7.376

9.  Altered Folate Homeostasis in Children with Down Syndrome: A Potential Basis for Enhanced Methotrexate Toxicity.

Authors:  Ryan S Funk; Nasreen J Talib; Kanecia O Zimmerman; Leon van Haandel; Mara L Becker
Journal:  J Pediatr       Date:  2020-02-25       Impact factor: 4.406

10.  Congenital gastrointestinal defects in Down syndrome: a report from the Atlanta and National Down Syndrome Projects.

Authors:  S B Freeman; C P Torfs; P A Romitti; M H Royle; C Druschel; C A Hobbs; S L Sherman
Journal:  Clin Genet       Date:  2008-11-17       Impact factor: 4.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.